TY - JOUR
T1 - Long-term survival of heart transplant recipients with lung cancer
T2 - The role of chest computed tomography screening
AU - Mohammadi, Siamak
AU - Bonnet, N.
AU - Leprince, P.
AU - Charbonneau, E.
AU - Berberian, G.
AU - Aslani, M.
AU - Silvaggio, G.
AU - Dorent, R.
AU - Pavie, A.
AU - Gandjbakhch, I.
PY - 2007/10
Y1 - 2007/10
N2 - Objective: We sought to evaluate the screening modality and outcome of lung cancer occurring in heart transplant recipients (HTR) during a 21-year period. Methods: We conducted a retrospective review to investigate the incidence, risk factors, screening modality, treatment, and outcomes in HTR with lung cancer. We compared them with a case-matched HTR control group. Results: Out of 829 recipients of heart transplants, 19 cases of bronchogenic carcinoma were found either by routine chest X-ray (n = 10), chest computed tomographic (CT) scanning (n = 4), or by assessment of clinical symptoms (n = 5). The mean time from transplantation to bronchogenic carcinoma diagnosis was 68.8 ± 42.4 months. A history of smoking was the only risk factor in HTR with bronchogenic carcinoma compared to their case-matched HTR control group (p <0.05). Of 18 patients with non-small cell lung cancer (NSCLC), 13 underwent surgery and 5 with advanced cancer underwent chemotherapy and/or radiotherapy. NSCLC was diagnosed by chest X-ray (n = 10), and 6 of these patients died after an average of 43.7 ± 62.2 months following cancer detection. NSCLC was also diagnosed on the basis of clinical symptoms (n = 4), and 2 of these patients died after a mean follow-up of 9 ± 4.2 months after cancer diagnosis. All 4 patients in whom cancer was detected by CT scan were alive at an average of 53.5 ± 36.7 months following cancer detection. The survival rates did not differ between the study and control groups (p = 0.5). Conclusions: Optimal outcomes of treatment for primary lung cancer after heart transplantation seem to be related to early detection. A high proportion of deaths from NSCLC may be prevented by chest CT scan screening.
AB - Objective: We sought to evaluate the screening modality and outcome of lung cancer occurring in heart transplant recipients (HTR) during a 21-year period. Methods: We conducted a retrospective review to investigate the incidence, risk factors, screening modality, treatment, and outcomes in HTR with lung cancer. We compared them with a case-matched HTR control group. Results: Out of 829 recipients of heart transplants, 19 cases of bronchogenic carcinoma were found either by routine chest X-ray (n = 10), chest computed tomographic (CT) scanning (n = 4), or by assessment of clinical symptoms (n = 5). The mean time from transplantation to bronchogenic carcinoma diagnosis was 68.8 ± 42.4 months. A history of smoking was the only risk factor in HTR with bronchogenic carcinoma compared to their case-matched HTR control group (p <0.05). Of 18 patients with non-small cell lung cancer (NSCLC), 13 underwent surgery and 5 with advanced cancer underwent chemotherapy and/or radiotherapy. NSCLC was diagnosed by chest X-ray (n = 10), and 6 of these patients died after an average of 43.7 ± 62.2 months following cancer detection. NSCLC was also diagnosed on the basis of clinical symptoms (n = 4), and 2 of these patients died after a mean follow-up of 9 ± 4.2 months after cancer diagnosis. All 4 patients in whom cancer was detected by CT scan were alive at an average of 53.5 ± 36.7 months following cancer detection. The survival rates did not differ between the study and control groups (p = 0.5). Conclusions: Optimal outcomes of treatment for primary lung cancer after heart transplantation seem to be related to early detection. A high proportion of deaths from NSCLC may be prevented by chest CT scan screening.
KW - Cardiomyopathy
KW - Heart and lung transplantation
KW - Thoracic surgery
UR - http://www.scopus.com/inward/record.url?scp=35548981731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35548981731&partnerID=8YFLogxK
U2 - 10.1055/s-2007-965306
DO - 10.1055/s-2007-965306
M3 - Article
C2 - 17902066
AN - SCOPUS:35548981731
VL - 55
SP - 438
EP - 441
JO - Thoracic and Cardiovascular Surgeon
JF - Thoracic and Cardiovascular Surgeon
SN - 0171-6425
IS - 7
ER -